Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough
Shots:
- The two P-III studies (COUGH-1 & -2) involves assessing of gefapixant (45/15mg- bid) vs PBO in 2-044 patients with refractory or unexplained chronic cough for 12 & 24wks. respectively
- In both the studies- gefapixant (45 mg) resulted in reduction of objectively measured 24hrs.-cough frequency @12 & 24wks. (18.45% & 14.64%)- reduction in cough frequency (62% & 63%)- estimated relative reduction (17.68% & 15.79% )- 77.1% improvement in cough-related QoL respectively- presented at Virtual ERS International Congress 2020
- The gefapixant (15mg- bid) did not meet its 1EPs in either study. Gefapixant (PO) is a selective P2X3 receptor antagonist- for the potential treatment of refractory or unexplained chronic cough
Ref: Merck | Image: Merck
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com